Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EPS (Weighted Average and Diluted) (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.0 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 168.99% to $0.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $0.01, a 109.38% increase, with the full-year FY2025 number at -$0.0, up 88.24% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.0 in Q1 2026 for Pharma-Bio Serv, up from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q3 2023 to a low of -$0.07 in Q4 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.01 (2022), compared with a mean of $0.0.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 3265.68% in 2024 and later skyrocketed 168.99% in 2026.
  • Pharma-Bio Serv's EPS (Weighted Average and Diluted) stood at $0.01 in 2022, then crashed by 127.23% to -$0.0 in 2023, then tumbled by 3265.68% to -$0.07 in 2024, then surged by 88.41% to -$0.01 in 2025, then surged by 112.5% to $0.0 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.0 (Q1 2026), -$0.01 (Q4 2025), and $0.01 (Q3 2025) per Business Quant data.